Charles River

Latest Headlines

Latest Headlines

Charles River spends $585M on WIL Research amid a buyout spree

Charles River Laboratories extended its run of acquisitions with a $585 million buyout of WIL Research, picking up a company the CRO said will expand its global footprint and bolster its manufacturing capabilities.

Charles River digs into Parkinson's R&D with Fox Foundation in tow

CRO Charles River Laboratories has expanded its relationship with the Michael J. Fox Foundation for Parkinson's Research to investigate a promising target that could lead to new treatments for the disease.

Fast-growing Charles River trades $36M for a drug discovery outfit

Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.

Charles River boosts its 2015 outlook after strong sales quarter

Charles River Laboratories returned to revenue growth on a wave of dealmaking, lifting its full-year guidance in response.

Charles River signs a trio of deals in drug discovery

Preclinical CRO Charles River Laboratories brought in three new discovery contracts with outfits funded by the Wellcome Trust, lending its expertise in early-stage drug development.

Charles River's revenue slips on slumping R&D demand

Charles River Laboratories saw its sales dip in the second quarter, but the early-stage specialist is counting on some recent acquisitions to spur growth for the full year.

Charles River doubles its EMD position with $212M deal for Celsis

Charles River Laboratories International expects to boost its position in pharma manufacturing with a $212 million deal to buy Celsis International, a company that specializes in endotoxin and microbial detection (EMD).

Charles River embraces discovery in management shake-up

Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.

Charles River rides M&A to a big revenue year

CRO giant Charles River Laboratories ended 2014 with a bang, boosting revenue by about 14% in the fourth quarter to close a deal-filled year.

Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.